Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland

The aim of the study was to verify the association of clinical relapses and brain activity with disability progression in relapsing/remitting multiple sclerosis patients receiving disease-modifying treatments in Poland. Disability progression was defined as relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and progression independent of relapses and brain MRI Activity (PIRMA). Data from the Therapeutic Program Monitoring System were analyzed. Three panels of patients were identified: R0, no relapse during treatment, and R1 and R2 with the occurrence of relapse during the first and the second year of treatment, respectively. In the R0 panel, we detected 4.6% PIRA patients at 24 months (p < 0.001, 5.0% at 36 months, 5.6% at 48 months, 6.1% at 60 months). When restricting this panel to patients without brain MRI activity, we detected 3.0% PIRMA patients at 12 months, 4.5% at 24 months, and varying from 5.3% to 6.2% between 36 and 60 months of treatment, respectively. In the R1 panel, RAW was detected in 15.6% patients at 12 months and, in the absence of further relapses, 9.7% at 24 months and 6.8% at 36 months of treatment. The R2 group was associated with RAW significantly more frequently at 24 months compared to the R1 at 12 months (20.7%; p < 0.05), but without a statistical difference later on. In our work, we confirmed that disability progression was independent of relapses and brain MRI activity.

Download Full-text

Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2019.05.017 ◽

2019 ◽

Vol 33 ◽

pp. 82-87 ◽

Cited By ~ 1

Author(s):

I. Dekker ◽

C.E. Leurs ◽

M.H.J. Hagens ◽

Z.L.E. van Kempen ◽

I. Kleerekooper ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Disability Progression ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Long-term effect of interferon-β use in real-world settings on disability progression: A series of 2,451 relapsing-remitting multiple sclerosis patients, Rennes, France

10.26226/morressier.59a3edacd462b8028d8954cb ◽

2017 ◽

Author(s):

Mathilde Lefort

Keyword(s):

Multiple Sclerosis ◽

Real World ◽

Term Effect ◽

Interferon Β ◽

Disability Progression ◽

Long Term Effect ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

Multiple Sclerosis Journal ◽

10.1177/1352458507085555 ◽

2008 ◽

Vol 14 (4) ◽

pp. 479-484 ◽

Cited By ~ 83

Author(s):

J Río ◽

À Rovira ◽

M Tintoré ◽

E Huerga ◽

C Nos ◽

...

Keyword(s):

Multiple Sclerosis ◽

Brain Mri ◽

Brain Lesion ◽

Brain Magnetic Resonance Imaging ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Brain Parenchymal ◽

Multiple Sclerosis Patients ◽

Mri Changes ◽

Relapsing Remitting Multiple Sclerosis

Objective Our objective in this study is to evaluate whether brain magnetic resonance imaging (MRI) performed at interferon-beta (IFN-β) onset and after 12 months allow us to identify relapsing–remitting multiple sclerosis (RRMS) patients with a disability increase in the first 2 years of therapy. Methods This is a prospective and longitudinal study of patients with RRMS treated with IFN-β. All patients included underwent brain MRI before the onset of therapy with IFN-β and 12 months after. MRI measures (T2, unenhanced T1-weighted and gadolinium-enhancing T1-weighted brain lesion load, brain parenchymal fraction) were undertaken at baseline and after 12 months. The number of active lesions (new or enlarging T2 plus gadolinium-enhancing brain lesions) was also assessed on the 12 months MRI scan. Expanded Disability Status Scale (EDSS) was scored every 3 months. We defined an increase in disability as an increase of at least 1 EDSS point confirmed and sustained during the first 2 years of therapy with IFN-β. Regression analysis was performed in order to identify MRI variables of response. Results We included 152 patients who were followed-up for at least 2 years. After 2 years of therapy, 24 patients (16%) had an increase in disability. The logistic regression model showed that active lesions in the scan performed at 12 months were the most important factor related with the increase of disability after 2 years of therapy (odds ratio 8.3, 95% confidence interval 3.1–21.9; p < 0.0001). Conclusions In RRMS patients treated with IFN-β the MRI changes occurring during the first year may have a prognostic value for identifying patients with a confirmed increase of disability after 2 years of therapy.

Download Full-text

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

Multiple Sclerosis International ◽

10.1155/2015/763418 ◽

2015 ◽

Vol 2015 ◽

pp. 1-7 ◽

Cited By ~ 4

Author(s):

Rocco Totaro ◽

Caterina Di Carmine ◽

Gianfranco Costantino ◽

Roberta Fantozzi ◽

Paolo Bellantonio ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Real World ◽

Convincing Evidence ◽

Clinical Relapse ◽

Disability Progression ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Objective. The aim of this prospective observational multicenter postmarketing study was to evaluate fingolimod efficacy in a real world clinical setting.Methods. One hundred forty-two subjects with relapsing-remitting multiple sclerosis (RRMS) were enrolled in three multiple sclerosis centers throughout Central and Southern Italy between January 2011 and September 2013. After enrollment, regular visits and EDSS assessment were scheduled every 3 months, and MRI scan was obtained every 12 months. Patients were followed up from 1 to 33 months (mean 14.95 ± 9.15 months). The main efficacy endpoints included the proportion of patients free from clinical relapses, from disability progression, from magnetic resonance imaging activity, and from any disease activity.Results. Out of 142 patients enrolled in the study, 88.1% were free from clinical relapse and 69.0% were free from disability progression; 68.5% of patients remained free from new or newly enlarging T2 lesions and 81.7% of patients were free from gadolinium enhancing lesions. Overall the proportion of patients free from any disease activity was 41.9%.Conclusions. Our data in a real world cohort are consistent with previous findings that yield convincing evidence for the efficacy of fingolimod in patients with RRMS.

Download Full-text